Ofatumumab versus Teriflunomide in Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Amit Bar‐Or et al.|New England Journal of Medicine|2020Cited by 706
How patients with multiple sclerosis acquire disabilityFred Lublin, Robert A Bermel, Dieter A. Häring et al.|Brain|2022Cited by 532
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, Ludwig Kappos, David H. Miller et al.|The Lancet|2016Cited by 449
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and IIJutta Gärtner, Ludwig Kappos, Stephen L. Hauser et al.|Multiple Sclerosis Journal|2022Cited by 103
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMSJeffrey A. Cohen, Gordon Francis, Frederik Barkhof et al.|Journal of Neurology|2013Cited by 88